Want to see CAPR full AI Analyst Report?
Capricor Therapeutics (CAPR) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Deramiocel (Cap-1002) | Muscular Dystrophy, Duchenne, Neuromuscular Diseases, Muscular Dystrophies, Nervous System Diseases, Muscular Diseases, Genetic Diseases, Inborn, Muscular Disorders, Atrophic, Genetic Diseases, X-Linked | Phase III | Active Not Recruiting | A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy | Nov 04, 2021 | ― |
| Cap-1002 | COVID19 | Phase II | Completed | Intravenous Infusion of CAP-1002 in Patients With COVID-19 | Oct 07, 2020 | ― |
| Deramiocel (Cap-1002) | Duchenne Muscular Dystrophy | Phase II | Active Not Recruiting | Open-label Extension of the HOPE-2 Trial | Jun 09, 2020 | ― |
| Cap-1002 | Muscular Dystrophy, Duchenne, Neuromuscular Diseases, Muscular Dystrophies, Nervous System Diseases, Muscular Diseases, Genetic Diseases, Inborn, Muscular Disorders, Atrophic, Genetic Diseases, X-Linked | Phase II | Completed | A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy | Jan 15, 2018 | ― |
| Allogeneic Cardiosphere-Derived Cells (Cap-1002) | Duchenne Muscular Dystrophy, Cardiomyopathy | Phase II | Completed | HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) | Jun 19, 2015 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Deramiocel (Cap-1002) | Phase III | Muscular Dystrophy, Duchenne, Neuromuscular Diseases, Muscular Dystrophies, Nervous System Diseases, Muscular Diseases, Genetic Diseases, Inborn, Muscular Disorders, Atrophic, Genetic Diseases, X-Linked | Active Not Recruiting | A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy | Nov 04, 2021 | ― |
| Cap-1002 | Phase II | COVID19 | Completed | Intravenous Infusion of CAP-1002 in Patients With COVID-19 | Oct 07, 2020 | ― |
| Deramiocel (Cap-1002) | Phase II | Duchenne Muscular Dystrophy | Active Not Recruiting | Open-label Extension of the HOPE-2 Trial | Jun 09, 2020 | ― |
| Cap-1002 | Phase II | Muscular Dystrophy, Duchenne, Neuromuscular Diseases, Muscular Dystrophies, Nervous System Diseases, Muscular Diseases, Genetic Diseases, Inborn, Muscular Disorders, Atrophic, Genetic Diseases, X-Linked | Completed | A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy | Jan 15, 2018 | ― |
| Allogeneic Cardiosphere-Derived Cells (Cap-1002) | Phase II | Duchenne Muscular Dystrophy, Cardiomyopathy | Completed | HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) | Jun 19, 2015 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Capricor Therapeutics, Inc. (CAPR) have in its pipeline
Capricor Therapeutics CAPR is currently developing the following drugs: Deramiocel (Cap-1002), Cap-1002, Allogeneic Cardiosphere-Derived Cells (Cap-1002). These drug candidates are in various stages of clinical development as the company works toward FDA approval.